Novel vaccine strategies against emerging viruses

Current Opinion in Virology

Volumn 3, Issue 2, 2013, Pages 210-216

  García Sastre, Adolfo ^a   Mena, Ignacio ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEIC ACID VACCINE; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ARTICLE; HUMAN; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 84880075363     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2013.02.001     Document Type: Review

References (57)

1. Soborg C, Molbak K, Doherty TM, Ulleryd P, Brooks T, Coenen C, van der Zeijst B: Vaccines in a hurry. Vaccine 2009, 27:3295-3298.
2. Bowick GC, McAuley AJ: Vaccine and adjuvant design for emerging viruses: mutations, deletions, segments and signaling. Bioeng Bugs 2011, 2:129-135.
3. Mbow ML, De Gregorio E, Valiante NM, Rappuoli R: New adjuvants for human vaccines. Curr Opin Immunol 2010, 22:411-416.
4. Schijns VE, Lavelle EC: Trends in vaccine adjuvants. Expert Rev Vaccines 2011, 10:539-550.
5. Pallister J, Middleton D, Wang LF, Klein R, Haining J, Robinson R, Yamada M, White J, Payne J, Feng YR et al.: A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge. Vaccine 2011, 29:5623-5630.
6. Nabel GJ, Fauci AS: Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat Med 2010, 16:1389-1391.
7. Gilbert SC: Advances in the development of universal influenza vaccines. Influenza Other Respir Viruses 2012 http://dx.doi.org/10.1111/irv.12013.
8. Kang SM, Kim MC, Compans RW: Virus-like particles as universal influenza vaccines. Expert Rev Vaccines 2012, 11:995-1007.
9. Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L, Kavita U, Stanberry L, Shaw A: Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 2011, 29:5145-5152.
10. Wang TT, Tan GS, Hai R, Pica N, Ngai L, Ekiert DC, Wilson IA, Garcia-Sastre A, Moran TM, Palese P: Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci USA 2010, 107:18979-18984.
11. Trumpfheller C, Longhi MP, Caskey M, Idoyaga J, Bozzacco L, Keler T, Schlesinger SJ, Steinman RM: Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity. J Intern Med 2012, 271:183-192.
12. Roldao A, Mellado MC, Castilho LR, Carrondo MJ, Alves PM: Virus-like particles in vaccine development. Expert Rev Vaccines 2010, 9:1149-1176.
13. Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, Haye K, Garcia-Sastre A, Palese P: Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio 2010, 1:e00018-10 http://dx.doi.org/10.1128/mBio.00018-10.
14. De Filette M, Fiers W, Martens W, Birkett A, Ramne A, Lowenadler B, Lycke N, Jou WM, Saelens X: Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 2006, 24:6597-6601.
15. Xia M, Tan M, Wei C, Zhong W, Wang L, McNeal M, Jiang X: A candidate dual vaccine against influenza and noroviruses. Vaccine 2011, 29:7670-7677.
16. Song JM, Wang BZ, Park KM, Van Rooijen N, Quan FS, Kim MC, Jin HT, Pekosz A, Compans RW, Kang SM: Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS ONE 2011, 6:e14538.
17. Andersson AM, Hakansson KO, Jensen BA, Christensen D, Andersen P, Thomsen AR, Christensen JP: Increased immunogenicity and protective efficacy of influenza m2e fused to a tetramerizing protein. PLoS ONE 2012, 7:e46395.
18. Hashemi H, Pouyanfard S, Bandehpour M, Noroozbabaei Z, Kazemi B, Saelens X, Mokhtari-Azad T: Immunization with M2edisplaying T7 bacteriophage nanoparticles protects against influenza A virus challenge. PLoS ONE 2012, 7:e45765.
19. Liu X, Guo J, Han S, Yao L, Chen A, Yang Q, Bo H, Xu P, Yin J, Zhang Z: Enhanced immune response induced by a potential influenza A vaccine based on branched M2e polypeptides linked to tuftsin. Vaccine 2012, 30:6527-6533.
20. Zhou C, Zhou L, Chen YH: Immunization with high epitope density of M2e derived from 2009 pandemic H1N1 elicits protective immunity in mice. Vaccine 2012, 30:3463-3469.
21. Burt FJ, Rolph MS, Rulli NE, Mahalingam S, Heise MT: Chikungunya: a re-emerging virus. Lancet 2012, 379:662-671.
22. Akahata W, Yang ZY, Andersen H, Sun S, Holdaway HA, Kong WP, Lewis MG, Higgs S, Rossmann MG, Rao S et al.: A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med 2010, 16:334-338.
23. Liu MA: Immunologic basis of vaccine vectors. Immunity 2010, 33:504-515.
24. Small JC, Ertl HC: Viruses - from pathogens to vaccine carriers. Curr Opin Virol 2011, 1:241-245.
25. Rollier CS, Reyes-Sandoval A, Cottingham MG, Ewer K, Hill AV: Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol 2011, 23:377-382.
26. Veits J, Wiesner D, Fuchs W, Hoffmann B, Granzow H, Starick E, Mundt E, Schirrmeier H, Mebatsion T, Mettenleiter TC et al.: Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza. Proc Natl Acad Sci USA 2006, 103:8197-8202.
27. Kortekaas J, de Boer SM, Kant J, Vloet RP, Antonis AF, Moormann RJ: Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector. Vaccine 2010, 28:4394-4401.
28. Harmsen MM, Antonis AF, Moormann RJ, Kortekaas J: Parenteral vaccination of mammalian livestock with Newcastle disease virus-based vector vaccines offers optimal efficacy and safety. Bioeng Bugs 2011, 2:58-62.
29. Fausther-Bovendo H, Mulangu S, Sullivan NJ: Ebolavirus vaccines for humans and apes. Curr Opin Virol 2012, 2:324-329.
30. Gunther S, Feldmann H, Geisbert TW, Hensley LE, Rollin PE, Nichol ST, Stroher U, Artsob H, Peters CJ, Ksiazek TG et al.: Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg. Germany. J Infect Dis 2011, 204(Suppl 3):S785-S790.
31. Sullivan NJ, Hensley L, Asiedu C, Geisbert TW, Stanley D, Johnson J, Honko A, Olinger G, Bailey M, Geisbert JB et al.: CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med 2011, 17:1128-1131.
32. Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G, Mulangu S, Hu Z, Andrews CA, Sheets RA et al.: A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010, 29:304-313.
33. Brennan B, Welch SR, McLees A, Elliott RM: Creation of a recombinant Rift Valley fever virus with a two-segmented genome. J Virol 2011, 85:10310-10318.
34. Lihoradova O, Kalveram B, Indran SV, Lokugamage N, Juelich TL, Hill TE, Tseng CT, Gong B, Fukushi S, Morikawa S et al.: The dominant-negative inhibition of double-stranded RNAdependent protein kinase PKR increases the efficacy of Rift Valley fever virus MP-12 vaccine. J Virol 2012, 86:7650-7661.
35. Kalveram B, Lihoradova O, Indran SV, Ikegami T: Using reverse genetics to manipulate the NSs gene of the Rift Valley fever virus MP-12 strain to improve vaccine safety and efficacy. J Vis Exp 2011:e3400.
36. Bird BH, Maartens LH, Campbell S, Erasmus BJ, Erickson BR, Dodd KA, Spiropoulou CF, Cannon D, Drew CP, Knust B et al.: Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep. J Virol 2011, 85:12901-12909.
37. Monath TP, Guirakhoo F, Nichols R, Yoksan S, Schrader R, Murphy C, Blum P, Woodward S, McCarthy K, Mathis D et al.: Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 2003, 188:1213-1230.
38. Dayan GH, Bevilacqua J, Coleman D, Buldo A, Risi G: Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults >/=50 years of age. Vaccine 2012, 30:6656-6664.
39. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA et al.: Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012, 380:1559-1567.
40. Konig P, Blome S, Gabriel C, Reimann I, Beer M: Innocuousness and safety of classical swine fever marker vaccine candidate CP7-E2alf in non-target and target species. Vaccine 2011, 30:5-8.
41. Shahabi V, Maciag PC, Rivera S, Wallecha A: Live, attenuated strains of Listeria and Salmonella as vaccine vectors in cancer treatment. Bioeng Bugs 2010, 1:235-243.
42. Bahey-El-Din M: Lactococcus lactis-based vaccines from laboratory bench to human use: an overview. Vaccine 2012, 30:685-690.
43. Li R, Lim A, Alonso S: Attenuated Bordetella pertussis BPZE1 as a live vehicle for heterologous vaccine antigens delivery through the nasal route. Bioeng Bugs 2011, 2:315-319.
44. Pei H, Liu J, Cheng Y, Sun C, Wang C, Lu Y, Ding J, Zhou J, Xiang H: Expression of SARS-coronavirus nucleocapsid protein in Escherichia coli and Lactococcus lactis for serodiagnosis and mucosal vaccination. Appl Microbiol Biotechnol 2005, 68:220-227.
45. Li R, Lim A, Ow ST, Phoon MC, Locht C, Chow VT, Alonso S: Development of live attenuated Bordetella pertussis strains expressing the universal influenza vaccine candidate M2e. Vaccine 2011, 29:5502-5511.
46. Liu MA, Wahren B, Karlsson Hedestam GB: DNA vaccines: recent developments and future possibilities. Hum Gene Ther 2006, 17:1051-1061.
47. Powell K: DNA vaccines - back in the saddle again? Nat Biotechnol 2004, 22:799-801.
48. Ledgerwood JE, Pierson TC, Hubka SA, Desai N, Rucker S, Gordon IJ, Enama ME, Nelson S, Nason M, Gu W et al.: A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis 2011, 203: 1396-1404.
49. Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, Bailer RT, Chakrabarti BK, Bailey MA, Gomez PL et al.: A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 2006, 13:1267-1277.
50. Boshra H, Lorenzo G, Rodriguez F, Brun A: A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNAR(S/S) mice upon lethal virus challenge. Vaccine 2011, 29:4469-4475.
51. Porter KR, Ewing D, Chen L, Wu SJ, Hayes CG, Ferrari M, Teneza-Mora N, Raviprakash K: Immunogenicity and protective efficacy of a vaxfectin-adjuvanted tetravalent dengue DNA vaccine. Vaccine 2012, 30:336-341.
52. Mallilankaraman K, Shedlock DJ, Bao H, Kawalekar OU, Fagone P, Ramanathan AA, Ferraro B, Stabenow J, Vijayachari P, Sundaram SG et al.: A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis 2011, 5:e928.
53. Ulmer JB, Mason PW, Geall A, Mandl CW: RNA-based vaccines. Vaccine 2012, 30:4414-4418.
54. Cao F, Li XF, Yu XD, Deng YQ, Jiang T, Zhu QY, Qin ED, Qin CF: A DNA-based West Nile virus replicon elicits humoral and cellular immune responses in mice. J Virol Methods 2011, 178:87-93.
55. Dodd KA, Bird BH, Metcalfe MG, Nichol ST, Albarino CG: Singledose immunization with virus replicon particles confers rapid robust protection against Rift Valley fever virus challenge. J Virol 2012, 86:4204-4212.
56. Kortekaas J, Oreshkova N, Cobos-Jimenez V, Vloet RP, Potgieter CA, Moormann RJ: Creation of a nonspreading Rift Valley fever virus. J Virol 2011, 85:12622-12630.
57. Vander Veen RL, Harris DL, Kamrud KI: Alphavirus replicon vaccines. Anim Health Res Rev 2012, 13:1-9. Diseases